Long-term outcomes, quality of life, and costs of treatment modalities for T1-T2 lip carcinomas.
Kira S Van HofMarlies WakkeeAniel SewnaikAimée F HerkendaalLisa TansHetty MastRenate R van den BosMarc A M MureauMarinella P J OffermanRobert J Baatenburg de JongPublished in: Oral diseases (2023)
Early-stage lip SCC has a good prognosis, with a disease-specific survival of 98.2% after a median follow-up of 36 months, there was a high QoL and satisfaction at long-term follow-up. Based on the costs and the risk of locoregional recurrences, we believe that, for most noncomplex lip SCCs, MMS would be the most logical treatment option.